Top Page
Oxford BioMedica
(OTC:OXB)
Oxford BioMedica (OXB) vs. iShares MSCI United Kingdom ETF (EWC)
Oxford BioMedica Business Overview & Revenue Model
Oxford BioMedica Earnings Call Summary
Oxford BioMedica Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 151.21M | 128.80M | 89.54M | 139.99M | 142.80M | 87.73M |
| Gross Profit | 66.38M | 53.02M | 39.73M | 69.18M | 82.64M | 46.07M |
| EBITDA | -1.07M | -14.33M | -148.62M | -10.86M | 33.22M | 3.92M |
| Net Income | -37.06M | -43.19M | -157.49M | -39.16M | 19.01M | -6.25M |
Balance Sheet | ||||||
| Total Assets | 216.32M | 231.64M | 252.34M | 460.18M | 237.23M | 183.93M |
| Cash, Cash Equivalents and Short-Term Investments | 53.88M | 60.65M | 103.72M | 141.31M | 109.02M | 46.98M |
| Total Debt | 105.42M | 108.76M | 111.46M | 114.28M | 9.34M | 13.85M |
| Total Liabilities | 183.59M | 171.16M | 174.51M | 223.99M | 49.89M | 71.18M |
| Stockholders Equity | 32.73M | 57.05M | 74.01M | 204.65M | 187.34M | 112.75M |
Cash Flow | ||||||
| Free Cash Flow | -13.69M | -58.12M | -38.35M | -28.91M | 15.99M | -10.24M |
| Operating Cash Flow | -9.50M | -50.63M | -28.52M | -12.62M | 25.45M | 3.12M |
| Investing Cash Flow | -4.63M | 5.63M | 2.81M | -56.46M | -9.46M | -10.80M |
| Financing Cash Flow | -12.63M | 2.91M | -12.70M | 98.62M | 46.21M | 38.19M |
Oxford BioMedica Technical Analysis
Oxford BioMedica Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £322.89M | 9.36 | 15.04% | ― | 1231.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £1.36B | ― | -26.01% | ― | 22.03% | 20.01% | |
47 Neutral | £260.33M | ― | ― | ― | ― | ― | |
46 Neutral | £732.06M | ― | -74.64% | ― | 55.44% | 75.77% | |
46 Neutral | £101.18M | -7.39 | ― | ― | ― | -94.12% | |
39 Underperform | £112.27M | -7.30 | -209.34% | ― | 198.49% | -26.66% |
Oxford BioMedica Corporate Events
Oxford Biomedica announced that its Chief Innovation Officer, Kyriacos Mitrophanous, exercised 26,210 LTIP options and sold the same number of shares at an average price of £5.758376 per share. This transaction, conducted on the London Stock Exchange, reflects ongoing managerial activities and may have implications for stakeholders monitoring insider transactions.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced that Dr. Heather Preston, a Non-Executive Director, has purchased 6,175 ordinary shares in the company. This transaction, conducted on the London Stock Exchange, highlights insider confidence in the company’s market position and future prospects. The purchase may positively influence stakeholder perceptions, reinforcing trust in the company’s strategic direction.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced the departure of Robert Ghenchev from its Board of Directors following his exit from Novo Holdings US. This change comes as the company continues to strengthen its position as a leading cell and gene therapy CDMO. Novo Holdings A/S, a major shareholder, retains the right to nominate a new director, subject to board approval, indicating ongoing strategic alignment and potential future developments.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced that Natalie Walter, Group General Counsel and Company Secretary, exercised 28,321 LTIP options and 39,679 DBP options, subsequently selling 68,000 shares at an average price of £6.116876 per share. This transaction, conducted on the London Stock Exchange, reflects the company’s adherence to EU Market Abuse Regulation requirements and highlights the ongoing financial activities of its senior management.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford BioMedica (OXB) has expanded its US presence by acquiring a commercial-scale viral vector manufacturing facility in North Carolina from Resilience. This acquisition aligns with OXB’s strategy to enhance its US GMP capacity, meeting growing client demand and strengthening its global CDMO network. The facility will support late-stage programs and commercial launches, particularly in the adeno-associated virus field, and is expected to bolster OXB’s competitive position in the global viral vector market. The acquisition is anticipated to support OXB’s long-term growth outlook and maintain existing financial guidance, with integration planning already underway.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica, a leading cell and gene therapy contract development and manufacturing organization (CDMO), specializes in viral vector manufacturing and collaborates with pharmaceutical and biotechnology companies worldwide.
Oxford BioMedica reported strong financial results for the first half of 2025, with a 44% increase in revenues to £73.2 million, driven by high demand for its CDMO services. The company has improved its profitability significantly, reducing its operating EBITDA loss and strengthening its balance sheet with new financial facilities and share placements. The company’s strategic initiatives, including expanding its US commercial-scale GMP capacity, are set to support its growth trajectory and enhance its market position.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £6.87 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica PLC announced that its issued share capital as of August 31, 2025, consists of 120,182,204 ordinary shares, with no shares held in treasury. This figure represents the total number of voting rights in the company and is relevant for shareholders determining their interest in OXB under the FCA’s rules. This announcement reflects OXB’s transparency in its operations and could impact shareholder decisions regarding their stakes in the company.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £930.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced that Kay Davies, a Non-Executive Director, inadvertently purchased and then sold 4,563 shares due to an administrative error by her financial advisers. The transactions were reversed, and any gains from the trade will be donated to charity. This incident highlights the importance of compliance and transparency in financial dealings, reinforcing OXB’s commitment to regulatory standards.
The most recent analyst rating on (GB:OXB) stock is a Hold with a £532.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica has announced the admission of 13,921,114 new Ordinary Shares to the Main Market of the London Stock Exchange, following a successful placing and subscription. This increases the company’s total issued share capital to 120,173,462 ordinary shares, impacting the total voting rights and potentially affecting shareholder notifications under FCA rules.
The most recent analyst rating on (GB:OXB) stock is a Hold with a £532.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced that Dr. Roch Doliveux, Non-Executive Director and Chair of the company, purchased 67,000 ordinary shares on the London Stock Exchange. This transaction, valued at approximately £301,332.50, reflects a strategic move by a key company leader, potentially signaling confidence in the company’s market position and future prospects.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica has successfully completed a placing of new ordinary shares, raising approximately £60 million. The funds will be used to expand its US commercial-scale capacity and improve process quality, addressing growing client demand across clinical phases. The placing was well-supported by both new and existing shareholders, and the shares are expected to be admitted to trading on the London Stock Exchange by 20 August 2025.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica has announced a £60 million equity raise to fund strategic investments in expanding its global CDMO network, particularly in the US. This expansion is expected to accelerate revenue growth and improve margins, with projected revenues of £220-240 million in FY2026 and 25-30% year-on-year growth in 2027 and 2028. The company aims to enhance its manufacturing capabilities and service offerings to meet growing client demand, positioning itself for stronger profitability and a larger share of the viral vector market.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced that its total issued share capital consists of 106,199,712 ordinary shares, with no shares held in treasury. This figure is crucial for shareholders to determine their interest in the company under the FCA’s rules, impacting how they manage their investments and disclosures.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica has secured a new four-year loan facility of up to $125 million from Oaktree Capital Management to support its global CDMO operations and growth strategy. This financial move will refinance an existing $50 million loan and provide flexibility for future business needs, reinforcing OXB’s position in the cell and gene therapy industry and demonstrating Oaktree’s confidence in the company’s strategic objectives and market leadership.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford BioMedica PLC has reported a strong start to the fiscal year 2025, with revenues for the first half reaching £70-73 million, marking a 38%-44% increase compared to the same period in 2024. The company has secured £149 million in new orders during the first half of 2025, more than doubling the previous year’s figures, and has reiterated its full-year revenue guidance of £160-170 million. The company’s multi-vector, multi-site strategy is progressing well, with increased demand for its services and a strong order book providing confidence in future growth. OXB is expanding its manufacturing and development capacity to meet growing demand, particularly in late-stage lentiviral programs, and is enhancing its global operations to support clients across various geographies and development stages.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.